The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Revolutionary technology will further boost OneSource’s scientific services offerings
Shivani Satish Wagh takes on the role of Joint Managing Director
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Strong topline growth driven by solid performance across key brands.
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
